Spectral Analysis Probe to Identify Glioblastoma Cells
24 janvier 2019 mis à jour par: University of Oklahoma
Pilot Study Utilizing a Spectral Analysis Probe to Identify Glioblastoma Cells in Patients With Glioblastoma Undergoing Standard Surgical Resection
This is a pilot, observational study to evaluate the intraoperative sensitivity of the Chaos Wand in detecting tumor tissue with glioblastoma disease.
Aperçu de l'étude
Statut
Résilié
Les conditions
Description détaillée
This is a pilot study to investigate if the Chaos Wand Spectral Diagnosis Probe can be used to identify Glioblastoma (GBM) cancer cells in patients undergoing standard surgical resection.
Eligible patients who have consented to the use of the Chaos Wand will be scheduled for surgery as standard cancer care for GBM.
During the surgical procedure, the Chaos Wand Spectral Diagnosis Probe will be utilized.
Fifteen intraoperative readings and signal recordings of GBM tissue will be taken.
The wand will only be used in areas that have already been deemed in need of resection due to GBM disease.
Each site identified for spectral analysis will be marked.
The wand does not come into contact with the brain at any point during this procedure.
Following surgical resection of the GBM tumor, tissue will be collected from the same 15 sites where the Chaos Wand was used.
The pathology report will be compared with the results of spectral analysis.
Type d'étude
Observationnel
Inscription (Réel)
12
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon non probabiliste
Population étudiée
The study population includes adult patients from the outpatient neurosurgery clinic or those who have presented through the University of Oklahoma emergency department and have been diagnosed with glioblastoma or are suspected of having glioblastoma based on pre-operative imaging.
The Stephenson Cancer Center will not exclude potential subjects from participating in this or any study solely on the basis of ethnic origin or socioeconomic status.
Every attempt will be made to enter all eligible patients into this protocol and therefore address the study objectives in a patient population representative of the entire patient population with GBM.
La description
Inclusion Criteria:
- Male or Female and over 18 years of age.
- Patients with histologically proven GBM who are newly diagnosed and eligible to undergo surgical treatment or patients who are suspected of having glioblastoma on pre-operative imaging which is subsequently confirmed by histopathology following tumor resection.
- Patients must be able to understand and willing to sign the informed consent document.
Exclusion Criteria:
- Patients with absence of glioblastoma.
- Patients who are not undergoing tumor resection.
- Patients who have prior brain radiotherapy
- Patients who have prior systemic chemotherapy
- Patients who are not willing to sign the informed consent and agree to participate.
- Patients who are pregnant or nursing
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean ratio of detecting glioblastoma cancer between the Chaos Wand spectral readings and histopathology as ground truth
Délai: 6 months
|
For participants newly diagnosed with glioblastoma multiforme or patients who are suspected of having glioblastoma on pre-operative imaging who consent to the use of the Chaos Wand during surgery, 15-20 spectral readings will be compared to histopathology as ground truth to measure the sensitivity of the Chaos Wand to detect glioblastoma.
For example, if a patient has 15 spectral readings but only 13 are histologically consistent with cancer, then the sensitivity of the wand would be 13/15*100 = 87%.
A mean value with standard deviation will be reported across all participants in the study.
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants experiencing post-operative intracranial hemorrhage following surgical resection of glioblastoma with use of the Chaos Wand during surgery
Délai: Up to 1 month following surgery
|
For participants newly diagnosed with glioblastoma multiforme or are suspected of having glioblastoma based on pre-operative imaging who consent to the use of the Chaos Wand during surgery, the number of cases of intracranial hemorrhage during the post-operative hospital course will be measured.
|
Up to 1 month following surgery
|
|
Number of participants experiencing post-operative ischemic stroke following surgical resection of glioblastoma with use of the Chaos Wand during surgery
Délai: Up to 1 month following surgery
|
For participants newly diagnosed with glioblastoma multiforme or are suspected of having glioblastoma based on pre-operative imaging who consent to the use of the Chaos Wand during surgery, the number of cases of ischemic stroke during the post-operative hospital course will be measured.
|
Up to 1 month following surgery
|
|
Number of participants experiencing post-operative surgical site infection following surgical resection of glioblastoma with use of the Chaos Wand during surgery
Délai: Up to 1 month following surgery
|
For participants newly diagnosed with glioblastoma multiforme or are suspected of having glioblastoma based on pre-operative imaging who consent to the use of the Chaos Wand during surgery, the number of cases of surgical site infection during the post-operative hospital course will be measured.
|
Up to 1 month following surgery
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Michael Sughrue, MD, University of Oklahoma
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
31 octobre 2017
Achèvement primaire (Réel)
30 septembre 2018
Achèvement de l'étude (Réel)
30 septembre 2018
Dates d'inscription aux études
Première soumission
12 septembre 2017
Première soumission répondant aux critères de contrôle qualité
25 septembre 2017
Première publication (Réel)
26 septembre 2017
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
25 janvier 2019
Dernière mise à jour soumise répondant aux critères de contrôle qualité
24 janvier 2019
Dernière vérification
1 janvier 2019
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 8285
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .